Biogen drops controversial Alzheimer ' s drug, focuses on other treatments

Biogen said it is discontinuing its controversial drug Aduhelm, so it can focus resources on other Alzheimer’s treatments that drive long-term growth. This includes shifting its priorities to its blockbuster drug Leqembi, which was developed with Japan's Eisai and approved in 2023. "As a pioneer…#biogen #aduhelm #leqembi #eisai #fda #irregularities #alzheimerassociation #newyorkcity #robertglatter #glatter
Source: Reuters: Health - Category: Consumer Health News Source Type: news